MANAGEMENT OF ENDOCRINE DISEASE: Hyperandrogenic states in women: pitfalls in laboratory diagnosis

Measuring total testosterone level is the first-line approach in assessing androgen excess in women. The main pitfalls in measuring testosterone relate to its low concentration and to the structural similarity between circulating androgens and testosterone, requiring accurate techniques with high specificity and sensitivity. These goals can be achieved by immunoassay using a specific anti-testosterone monoclonal antibody, ideally after an extraction step. Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) will be commonly used for measuring testosterone, providing optimal accuracy with a low limit of detection. Yet, the pitfalls of these two techniques are well identified and must be recognized and systematically addressed. In general, laboratories using direct testosterone immunoassay and mass spectrometry need to operate within a quality framework and be actively engaged in external quality control processes and standardization, so as to ensure appropriate interpretation irrespective of the particular laboratory. Circulating testosterone is strongly bound to sex-hormone-binding globulin (SHBG), and SHBG levels are typically low in overweight hyperandrogenic patients. Thus, low SHBG may decrease circulating testosterone to normal values, which will mask androgen excess status. One way to avoid this pitfall, awaiting direct free testosterone assays that are yet to be developed, is to measure SHBG and calculate free testosterone. A few other pitfalls will be discussed in this review, including those of adrenal androgen exploration, with the aim of helping clinicians to better handle laboratory investigation of androgen excess disorders in women.

[1]  Frederick C W Wu,et al.  A Reappraisal of Testosterone's Binding in Circulation: Physiological and Clinical Implications. , 2017, Endocrine reviews.

[2]  J. W. Allwood,et al.  AKR1C3-Mediated Adipose Androgen Generation Drives Lipotoxicity in Women With Polycystic Ovary Syndrome , 2017, The Journal of clinical endocrinology and metabolism.

[3]  P. Chanson,et al.  High-dose biotin therapy leading to false biochemical endocrine profiles: validation of a simple method to overcome biotin interference , 2017, Clinical chemistry and laboratory medicine.

[4]  M. Polak,et al.  False biochemical diagnosis of hyperthyroidism in streptavidin-biotin-based immunoassays: the problem of biotin intake and related interferences , 2017, Clinical chemistry and laboratory medicine.

[5]  K. Storbeck,et al.  A new dawn for androgens: Novel lessons from 11-oxygenated C19 steroids , 2017, Molecular and Cellular Endocrinology.

[6]  A. Kulle,et al.  Steroid hormone analysis in diagnosis and treatment of DSD: position paper of EU COST Action BM 1303 ‘DSDnet’ , 2017, European journal of endocrinology.

[7]  Reilly,et al.  11-Oxygenated C19 Steroids Are the Predominant Androgens in Polycystic Ovary Syndrome , 2016, The Journal of clinical endocrinology and metabolism.

[8]  F. Distelmaier,et al.  More on Biotin Treatment Mimicking Graves' Disease. , 2016, The New England journal of medicine.

[9]  J. Kaufman,et al.  Sex hormone-binding globulin regulation of androgen bioactivity in vivo: validation of the free hormone hypothesis , 2016, Scientific Reports.

[10]  K. Storbeck,et al.  High-throughput analysis of 19 endogenous androgenic steroids by ultra-performance convergence chromatography tandem mass spectrometry. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[11]  F. Distelmaier,et al.  Biotin Treatment Mimicking Graves' Disease. , 2016, The New England journal of medicine.

[12]  M. Elston,et al.  Factitious Graves' Disease Due to Biotin Immunoassay Interference-A Case and Review of the Literature. , 2016, The Journal of clinical endocrinology and metabolism.

[13]  L. Zanotti,et al.  Defining Hyperandrogenism in Women With Polycystic Ovary Syndrome: A Challenging Perspective. , 2016, The Journal of clinical endocrinology and metabolism.

[14]  R. Simó,et al.  Novel insights in SHBG regulation and clinical implications , 2015, Trends in Endocrinology & Metabolism.

[15]  M. Goodarzi,et al.  DHEA, DHEAS and PCOS , 2015, The Journal of Steroid Biochemistry and Molecular Biology.

[16]  B. Obermayer-Pietsch,et al.  Hyperandrogenemia in Polycystic Ovary Syndrome: Exploration of the Role of Free Testosterone and Androstenedione in Metabolic Phenotype , 2014, PloS one.

[17]  F. Keleştimur,et al.  The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. , 2014, European journal of endocrinology.

[18]  A. Roux,et al.  Inverse relationship between hSHBG affinity for testosterone and hSHBG concentration revealed by surface plasmon resonance , 2014, Molecular and Cellular Endocrinology.

[19]  Farfia Capper,et al.  Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione , 2014, The Journal of clinical endocrinology and metabolism.

[20]  U. Stenman Standardization of hormone determinations. , 2013, Best practice & research. Clinical endocrinology & metabolism.

[21]  C. Sturgeon External quality assessment of hormone determinations. , 2013, Best practice & research. Clinical endocrinology & metabolism.

[22]  M. Murad,et al.  Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline , 2013, The Journal of clinical endocrinology and metabolism.

[23]  B. Keevil,et al.  Novel liquid chromatography tandem mass spectrometry (LC-MS/MS) methods for measuring steroids. , 2013, Best practice & research. Clinical endocrinology & metabolism.

[24]  J. Faix Principles and pitfalls of free hormone measurements. , 2013, Best practice & research. Clinical endocrinology & metabolism.

[25]  F. Keleştimur,et al.  Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. , 2012, Human reproduction update.

[26]  S. Krawetz,et al.  Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutism. , 2010, The Journal of clinical endocrinology and metabolism.

[27]  B. Sternfeld,et al.  The polycystic ovary post-rotterdam: a common, age-dependent finding in ovulatory women without metabolic significance. , 2010, The Journal of clinical endocrinology and metabolism.

[28]  H. Vesper,et al.  Toward excellence in testosterone testing: a consensus statement. , 2010, The Journal of clinical endocrinology and metabolism.

[29]  F. Stanczyk,et al.  Advantages and challenges of mass spectrometry assays for steroid hormones , 2010, The Journal of Steroid Biochemistry and Molecular Biology.

[30]  C. Seger,et al.  Pitfalls associated with the use of liquid chromatography-tandem mass spectrometry in the clinical laboratory. , 2010, Clinical chemistry.

[31]  G. Lavery,et al.  Journal of Steroid Biochemistry and Molecular Biology , 2022 .

[32]  E. Diamandis,et al.  Direct measurement of serum free testosterone by ultrafiltration followed by liquid chromatography tandem mass spectrometry. , 2010, Clinical biochemistry.

[33]  A. Balen,et al.  Defining hyperandrogenism in polycystic ovary syndrome: measurement of testosterone and androstenedione by liquid chromatography-tandem mass spectrometry and analysis by receiver operator characteristic plots. , 2010, European Journal of Endocrinology.

[34]  R. Cohen,et al.  Recommendations for investigation of hyperandrogenism. , 2010, Annales d'endocrinologie.

[35]  W. Salameh,et al.  Validation of a total testosterone assay using high-turbulence liquid chromatography tandem mass spectrometry: Total and free testosterone reference ranges , 2010, Steroids.

[36]  V. Tardy,et al.  Detection and management of late-onset 21-hydroxylase deficiency in women with hyperandrogenism. , 2010, Annales d'endocrinologie.

[37]  C. Ohlsson,et al.  Are there any sensitive and specific sex steroid markers for polycystic ovary syndrome? , 2010, The Journal of clinical endocrinology and metabolism.

[38]  CM Burt Solorzano,et al.  Hyperandrogenaemia in adolescent girls: origins of abnormal gonadotropin‐releasing hormone secretion , 2010, BJOG : an international journal of obstetrics and gynaecology.

[39]  N. Hanley,et al.  Inactivating PAPSS2 mutations in a patient with premature pubarche. , 2009, The New England journal of medicine.

[40]  R. Azziz,et al.  Adrenal function during childhood and puberty in daughters of women with polycystic ovary syndrome. , 2009, The Journal of clinical endocrinology and metabolism.

[41]  R. Azziz,et al.  Effect of insulin and testosterone on androgen production and transcription of SULT2A1 in the NCI-H295R adrenocortical cell line. , 2009, Fertility and sterility.

[42]  Michael R. Kennedy,et al.  Type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) contributes to testosterone production in the adrenal reticularis. , 2009, The Journal of clinical endocrinology and metabolism.

[43]  J. Golmard,et al.  Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members. , 2009, The Journal of clinical endocrinology and metabolism.

[44]  R. Azziz,et al.  Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome. , 2009, Fertility and sterility.

[45]  David J Handelsman,et al.  Predictive accuracy and sources of variability in calculated free testosterone estimates , 2009, Annals of clinical biochemistry.

[46]  R. Norman,et al.  The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. , 2009, Fertility and sterility.

[47]  G. Hammond,et al.  Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone-binding globulin gene. , 2007, The Journal of clinical investigation.

[48]  A. Lanzone,et al.  Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome. , 2007, Fertility and sterility.

[49]  B. Keevil,et al.  The impact of simultaneous measurement of testosterone and androstenedione in women with suspected androgen excess. , 2007, Clinical chemistry.

[50]  H. Raff,et al.  Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. , 2007, The Journal of clinical endocrinology and metabolism.

[51]  Maria I New,et al.  Extensive clinical experience: nonclassical 21-hydroxylase deficiency. , 2006, The Journal of clinical endocrinology and metabolism.

[52]  G. Hammond,et al.  Evidence That Fibulin Family Members Contribute to the Steroid-dependent Extravascular Sequestration of Sex Hormone-binding Globulin* , 2006, Journal of Biological Chemistry.

[53]  F. Stanczyk Diagnosis of hyperandrogenism: biochemical criteria. , 2006, Best practice & research. Clinical endocrinology & metabolism.

[54]  R. Rosenfield Clinical practice. Hirsutism. , 2005, The New England journal of medicine.

[55]  H. Schulz,et al.  Role of Endocytosis in Cellular Uptake of Sex Steroids , 2005, Cell.

[56]  David J Handelsman,et al.  Empirical estimation of free testosterone from testosterone and sex hormone-binding globulin immunoassays. , 2005, European journal of endocrinology.

[57]  A. Valleix,et al.  Development of a highly sensitive and specific new testosterone time-resolved fluoroimmunoassay in human serum , 2004, Steroids.

[58]  K. Taylor,et al.  Androgen excess in women: experience with over 1000 consecutive patients. , 2004, The Journal of clinical endocrinology and metabolism.

[59]  D. Schoenfeld,et al.  Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. , 2004, The Journal of clinical endocrinology and metabolism.

[60]  D. Ehrmann,et al.  Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. , 2003, Fertility and sterility.

[61]  C. Strott Sulfonation and molecular action. , 2002, Endocrine reviews.

[62]  R. Saad,et al.  Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. , 2002, The Journal of clinical endocrinology and metabolism.

[63]  J. L. San Millán,et al.  Receiver operating characteristic analysis of the performance of basal serum hormone profiles for the diagnosis of polycystic ovary syndrome in epidemiological studies. , 2001, European journal of endocrinology.

[64]  W. Rosner,et al.  An extraordinarily inaccurate assay for free testosterone is still with us. , 2001, The Journal of clinical endocrinology and metabolism.

[65]  V. Rohmer,et al.  21-Hydroxylase-deficient nonclassic adrenal hyperplasia is a progressive disorder: a multicenter study. , 2000, American journal of obstetrics and gynecology.

[66]  T. Arora,et al.  Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. , 2000, The Journal of clinical endocrinology and metabolism.

[67]  R. Azziz,et al.  A multicenter study of women with nonclassical congenital adrenal hyperplasia: relationship between genotype and phenotype. , 2000, Molecular genetics and metabolism.

[68]  A. Vermeulen,et al.  A critical evaluation of simple methods for the estimation of free testosterone in serum. , 1999, The Journal of clinical endocrinology and metabolism.

[69]  G. Beall,et al.  The use of a sensitive equilibrium dialysis method for the measurement of free testosterone levels in healthy, cycling women and in human immunodeficiency virus-infected women. , 1998, The Journal of clinical endocrinology and metabolism.

[70]  J. Goméz,et al.  Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. , 1997, The Journal of clinical endocrinology and metabolism.

[71]  W. Oelkers,et al.  Insulin-like growth factors enhance steroidogenic enzyme and corticotropin receptor messenger ribonucleic acid levels and corticotropin steroidogenic responsiveness in cultured human adrenocortical cells. , 1996, The Journal of clinical endocrinology and metabolism.

[72]  V. Toscano,et al.  Insulin infusion amplifies 17 alpha-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. , 1996, The Journal of clinical endocrinology and metabolism.

[73]  W. Miller,et al.  Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[74]  G. Schaison,et al.  The control of gonadotrophin secretion by ovarian steroids. , 1993, Human reproduction.

[75]  J. Crave,et al.  Pathophysiology of sex hormone binding globulin (SHBG): Relation to insulin , 1991, The Journal of Steroid Biochemistry and Molecular Biology.

[76]  C. Longcope,et al.  Metabolic clearance rate of dehydroepiandrosterone sulfate, its metabolism to testosterone, and its intrafollicular metabolism to dehydroepiandrosterone, androstenedione, testosterone, and dihydrotestosterone in vivo. , 1991, The Journal of clinical endocrinology and metabolism.

[77]  G. Hammond Molecular properties of corticosteroid binding globulin and the sex-steroid binding proteins. , 1990, Endocrine reviews.

[78]  M. Pugeat,et al.  Radioimmunoassay of testosterone not bound to sex-steroid-binding protein in plasma. , 1989, Clinical chemistry.

[79]  C. Mendel The free hormone hypothesis: a physiologically based mathematical model. , 1989, Endocrine reviews.

[80]  J. Thalabard,et al.  Effects of a pure antiandrogen on gonadotropin secretion in normal women and in polycystic ovarian disease. , 1989 .

[81]  F. Duron,et al.  Determination of testosterone in serum not bound by sex-hormone-binding globulin: diagnostic value in hirsute women. , 1988, Clinical chemistry.

[82]  W. Pardridge Selective Delivery of Sex Steroid Hormones to Tissues In Vivo by Albumin and by Sex Hormone‐Binding Globulin a , 1988, Annals of the New York Academy of Sciences.

[83]  J. Fiet,et al.  Comparison of basal and adrenocorticotropin-stimulated plasma 21-deoxycortisol and 17-hydroxyprogesterone values as biological markers of late-onset adrenal hyperplasia. , 1988, The Journal of clinical endocrinology and metabolism.

[84]  C. Longcope Adrenal and gonadal androgen secretion in normal females. , 1986, Clinics in endocrinology and metabolism.

[85]  W. Pardridge 4 Serum bioavailability of sex steroid hormones , 1986 .

[86]  J. Dunn,et al.  Transport of steroid hormones: interaction of 70 drugs with testosterone-binding globulin and corticosteroid-binding globulin in human plasma. , 1981, The Journal of clinical endocrinology and metabolism.

[87]  J. Dunn,et al.  Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. , 1981, The Journal of clinical endocrinology and metabolism.

[88]  G. Hammond,et al.  Estimation of the percentage of free steroid in undiluted serum by centrifugal ultrafiltration-dialysis. , 1980, The Journal of biological chemistry.

[89]  S. C. Yen,et al.  REVIEW ARTICLE: THE POLYCYSTIC OVARY SYNDROME , 1980 .

[90]  R. Rosenfield Plasma free androgen patterns in hirsute women and their diagnostic implications. , 1979, The American journal of medicine.

[91]  D. Fukushima,et al.  24-Hour secretory pattern of dehydroisoandrosterone and dehydroisoandrosterone sulfate. , 1975, The Journal of clinical endocrinology and metabolism.

[92]  R. Tremblay,et al.  Plasma concentrations of free and non-TeBG bound testosterone in women on oral contraceptives. , 1974, Contraception.

[93]  M. Forest,et al.  Metabolic clearance rate and blood production rate of testosterone and dihydrotestosterone in normal subjects, during pregnancy, and in hyperthyroidism. , 1972, The Journal of clinical investigation.

[94]  A. Vermeulen,et al.  The apparent free testosterone concentration, an index of androgenicity. , 1971, The Journal of clinical endocrinology and metabolism.

[95]  C. Bardin,et al.  The metabolic clearance rate and origin of plasma dihydrotestosterone in man and its conversion to the 5-alpha-androstanediols. , 1971, The Journal of clinical investigation.

[96]  S. Yen,et al.  Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease. , 1970, The Journal of clinical endocrinology and metabolism.

[97]  A. Vermeulen,et al.  Capacity of the Testosterone-Binding Globulin in Human Plasma and Influence of Specific Binding of Testosterone on Its Metabolic Clearance Rate , 1969 .

[98]  M. Forest,et al.  Percentage binding of testosterone, androstenedione and dehydroisoandrosterone in human plasma. , 1968, Steroids.

[99]  I. Bird,et al.  Fetal programming of adrenal androgen excess: lessons from a nonhuman primate model of polycystic ovary syndrome. , 2008, Endocrine development.

[100]  M. Rizzo,et al.  Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. , 2006, The Journal of clinical endocrinology and metabolism.

[101]  J. L. San Millán,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society A Prospective Study of the Prevalence of the Polycystic Ovary Syndrome in Unselected Caucasian Women from Spain* , 1999 .

[102]  G. Morgante,et al.  Hormonal effects of flutamide in young women with polycystic ovary syndrome. , 1998, The Journal of clinical endocrinology and metabolism.

[103]  D. Hoffman,et al.  Embryonic morphology and rate of implantation of human embryos following co-culture on bovine oviductal epithelial cells. , 1993, Human reproduction.

[104]  C. Longcope,et al.  Metabolic clearance rates and interconversions of estrone and 17beta-estradiol in normal males and females. , 1968, The Journal of clinical investigation.

[105]  I. Stein,et al.  Amenorrhea associated with bilateral polycystic ovaries , 1935 .